vivo Science is proud to continue its business unhindered, despite the tragic COVID 19 pandemic and that no delays in studies are expected.
According to our business continuity plan we are able to work with 2 independent and separate teams, with the option of a fully quarantined „working core team“ in case the situation will escalate.
New Center of Competence for Innovative Diabetes Therapy (KomIT) funded by NRW and EU
Gronau, March 2019
Over the next three years, vivo Science GmbH will work closely with a consortium of eight partners from industry and academia (molecular biology and cellular metabolic physiology) in the search for new drugs to treat diabetes. At the German Diabetes Center (DDZ), a new competence center will be set up in the next three years with funds from the state of North Rhine-Westphalia and the EU amounting to around 3.5 million euros. The aim of the Center, coordinated by the DDZ, is to efficiently translate innovative research results into clinical use to improve patient diabetes management.
The rapidly increasing number of diabetes patients in Germany, as well as the associated socio-economic burden on the healthcare system, urgently requires the development of new approaches to causal therapies.
„Together with our partners we aim to establish a sustainable infrastructure, to bring innovative approaches of diabetes therapy rapidly and directly to the patients“ explains Prof. Michael Roden, scientific Director of the German Diabetes Center and coordinator of the new Center of Competence for Innovative Diabetes Therapy (KomIT). „Our joint activities aim to bundle expertise, finally leading to scientific and technological break-throughs in diabetes research“. In addition to vivo Science and the German Diabetes Center, the other partners are: Algiax Pharmaceuticals GmbH, Taros Chemicals GmbH & Co. KG, Lead Discovery Center GmbH (LDC), A & M Labor für Analytik und Metabolismusforschung Service GmbH, PROFIL Institut für Stoffwechselforschung GmbH, and TU Dortmund with the Drug Discovery Hub Dortmund (DDHD).
In North Rhine-Westphalia, excellent basic research in the field of clinical-experimental diabetes studies is conducted for a long time. However, translation of these results into clinical applications is not yet sufficient to generate an economic boost. For start-ups and small companies with high innovation potential it is often not possible to carry out extensive experimental and clinical research with sufficient critical mass. At this point, the new Center of Competence provides strategic support. Leading idea is to build up a sustainable infrastructure that combines expertise from management, medicinal chemistry, preclinical and analytical studies, toxicology and physiology, up to clinical testing.
This novel research infrastructure provides a strong boost for the pharma and biotech sector in Northrhine-Westphalia and supports innovation and competitiveness in NRW. The project is funded within the program „EFRE.NRW – Investitionen in Wachstum und Beschäftigung“ supported by NRW and the Europen Union.
Meet us at BIO-EUROPE 2018 in Copenhagen from the 5. to 7. November 2018.
We are pleased to welcome you directly at our booth at the BIO.NRW community stand or for an individual appointment please feel free to contact us (firstname.lastname@example.org)
For more information about the BIO-EUROPE click here
Meet us at EUROTOX 2018 in Brussels from the 2. to 5. September 2018.
We are pleased to welcome you at our booth # 58
For more information about the EUROTOX click here
TEXCELL acquires German company vivo Science GmbH
Evry/Gronau on May 17th, 2016
On 2 May 2016 TEXCELL of France signed a contract for the acquisition of Germany’s vivo Science GmbH, a GLP/GMP-compliant laboratory specialized in toxicology, immunology and virology in vivo studies.
Texcell, supplier of services in viral security and immunology, is buying vivo Science, a German company that provides services to the pharmaceutical industry (CRO) and has specialized over the last 15 years in immunogenicity, immunotoxicology and virology in vivo assays. The acquisition is part of Texcell‘s aim of expanding its portfolio of services in the areas of preclinical and clinical research.
Thanks to its experience in the creation of biosecurity tests and viral validations, over the last 20 years Texcell has evaluated a large number of products, some of which are now registered with the FDA, EMA and MHW.
The acquisition of vivo Science is also a new and powerful marker of the company’s expansion on the international stage.
« With this acquisition the Texcell group is growing and pursuing its international strategy in line with its motto: Texcell everywhere and near the customers » says Bernard PLICHON, president and chief executive officer of the Texcell group.
Recognized worldwide, in 2010 Texcell acquired a majority stake in a US company based in Frederick (Maryland) that has become Texcell North America. It has also developed commercial partnerships in Asia with companies based in South Korea and, more recently, Taiwan.
Today Texcell and vivo Science together represent a turnover of more than €10 million and employ some 90 people. The « vivo Science » brand will be kept and the company integrated within the Texcell group.
In their own words:
« In acquiring vivo Science Texcell is going forward with its policy of internalizing virology and
immunology services while at the same time reinforcing its presence in Germany, the largest biotech
market in Europe, » says Grégoire Tauveron, Texcell export Director.
Olivier Cena, Texcell’s Director of Immunology for Europe, is enthusiastic: « It is a fantastic operation and a crucial step in Texcell Group’s international expansion in immunology services. By adding Vivo Science’s infrastructure we shall be able to supply a range of services that meet the demands of the market. Our aim is to become a key player in immunology and immunotoxicity in Europe. »
« The coming-together of Texcell and vivo Science is an excellent opportunity for the company and the staff of vivo Science, » CEO André Rademaekers emphasizes.
« The synergy is so significant that success is bound to follow for both companies, » say vivo Science shareholders Stefan Fischer and Jürgen Schumacher, who are transferring the whole of their stakes to Texcell SA.
TEXCELL, a spin-off from the Pasteur Institute, is based at EVRY’s Biocluster Genopole near Paris with more than 2200 m2 of offices and laboratories (L2 & L3). It provides a wide range of services in viral safety and immunological tracking in compliance with Good Laboratory Practices and Good Manufacturing Practices.
Head office : Genavenir 5 – 1, rue Pierre Fontaine 91058 Evry cedex – France
Website : www.texcell.com
vivo Science is a service company in the pharmaceutical industry (CRO) offering GLP/GMP toxicology in vivo studies and is specialized in immunogenicity, immunotoxicology and virology in vivo assays.
Head office: Gronau, Fabrikstrasse 3, 48599 Gronau – Germany